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Simple Summary: Antimicrobial resistance continues to be a major global health threat. It is
estimated by the WHO that 700,000 people die each year because of drug resistance, and this is
predicted to rise to 10 million by 2050. As well as the increased cost, which is forecast to exceed
$100 trillion, as more expensive drugs have to be deployed, illnesses often last longer and require
hospital treatment. This, in turn, increases the strain on often-inadequate healthcare systems. As
resistances continue to grow, finding alternatives is crucial. This review showed that nitroreductases
play a role in drug activation but are also associated with resistance mechanisms. These mechanisms
require further investigation to fully understand them before they can be utilised against multidrug-
resistant organisms. This will depend on committed collaborations between the private and public
sector to translate academic research into the clinic.
Abstract: Antimicrobial resistance is a major challenge facing modern medicine, with an estimated
700,000 people dying annually and a global cost in excess of $100 trillion. This has led to an increased
need to develop new, effective treatments. This review focuses on nitroimidazoles, which have seen
a resurgence in interest due to their broad spectrum of activity against anaerobic Gram-negative and
Gram-positive bacteria. The role of nitroreductases is to activate the antimicrobial by reducing the
nitro group. A decrease in the activity of nitroreductases is associated with resistance. This review
will discuss the resistance mechanisms of different disease organisms, including Mycobacterium tuber-
culosis, Helicobacter pylori and Staphylococcus aureus, and how these impact the effectiveness of specific
nitroimidazoles. Perspectives in the field of nitroimidazole drug development are also summarised.
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1. Introduction
Nitroreductases (NTR) are a family of proteins involved in the reduction of nitro-
containing compounds [1]. The flexibility of these enzymes comprises their usefulness in a
variety of biological and medical applications. These include environmental decontami-
nation using bioremediation [2]; various cancer therapies such as gene and viral-directed
prodrugs [3–7] and probes for detecting hypoxia in tumours [8–11], antiparasitics [12,13],
herbicides [14] and for the detection of explosives [15]. For a more detailed review of the
many uses of nitroreductases, see the papers by Kumari et al. [11], Zhang et al. [4] and
Nepali et al. [16].
Nitroreductases can be divided into two groups: flavin reductases [17] and those from
enteric bacteria [18]. Typical NTRs share similar biochemical properties; they usually occur
as a homodimer, contain flavin mononucleotide (FMN) as a cofactor and catalyse using the
ping-pong bi-bi kinetic mechanism [1,19]. The bacterial NTRs can be further split into Type
I, oxygen-insensitive and type II, which are oxygen-sensitive, as illustrated in Figure 1 [20].
Bacteria can contain both type I and II, although the most studied are those enzymes that
belong to type I [19]. The oxygen-insensitive NTRs can be further divided into major and
minor protein groups. The minor group can utilise nicotinamide adenine dinucleotide
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(NAPH) or nicotinamide adenine dinucleotide phosphate (NADPH), while the major group
can utilise NADPH only as the electron donor [21]. The most studied examples of the
major and minor groups are the Escherichia coli NfsA and NfsB enzymes [21].
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stress, as the enzyme NfsA is regulated by the SoxRS system, which is involved in the 
prevention of oxidative damage [24,25]. The range and adaptability of NTRs have enabled 
some of these enzymes to specialise in different metabolic functions without necessarily 
losing the other reductase activities [19]. Therefore, while some NTRs are associated with 
specific metabolic pathways or the reduction of different nitroaromatic compounds, oth-
ers may be active in processes such as oxidative stress response or bioluminescence [26]. 
Due to the ability of NTRs to affect the toxic, mutagenic and carcinogenic characteristics 
of many nitroaromatics, nitrofuran derivatives have been used to develop a group of an-
timicrobials commonly knowns as nitroimidazoles [27]. 
Nitroimidazoles have seen a resurgence in interest due to their broad spectrum of 
activity against anaerobic Gram-negative and Gram-positive bacteria. They are particu-
larly being seen as important in the battle against antibiotic resistance. Resistance to anti-
biotics is a major challenge facing modern medicine, and its importance was highlighted 
in 2016 when it was a topic for discussion at the United Nations General Assembly [28]. It 
is estimated that 700,000 people die each year because of infections that are resistant to 
current antibiotics and that this figure is predicted to rise to 10 million annually by 2050, 
with the global cost forecast to exceed $100 trillion over the next few decades [29]. The 
overuse of antibiotics in both clinical and agricultural settings has accelerated the process 
of resistance [29,30]. Perhaps the most widely known antibiotic is penicillin, which was 
discovered by Fleming in 1928, although it was not produced on any great scale until 1940 
[30]. Most current antimicrobials were discovered between the 1940s and 1970s, including 
nitroimidazoles in the early 1950s, when azomycin was isolated from a crude extract of 
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NAD: ic ti i dinucleotide and NADPH: nicotinamide adeni e dinucleotide phosphate.
The physiological functions of NTRs are not completely understood, but several have
been pro osed f r oxygen-insensitive bact rial NTRs [19]. It has been ass m d that they
have a role to play in detoxification, as they reduce a broad range of co pounds [19].
Some are involved in specific degradation pathways, such as nitrobenzene red ctase and
nitrophenol reductase [22,23]. NTRs may also be involved in the response to oxidative
stress, as the enzyme NfsA is regulated by the SoxRS system, which is involved in the
prevention of oxidative damage [24,25]. The range and adaptability of NTRs have enabled
some of these enzymes to specialise in different metabolic functions without necessarily
losing the other reductase activities [19]. Therefore, while some NTRs are associated with
specific metabolic pathways or the reduction of different nitroaromatic compounds, others
may be active in processes such as oxidative stress response or bioluminescence [26]. Due
to the ability of NTRs to affect the toxic, mutagenic and carcinogenic characteristics of many
nitroaromatics, nitrofuran derivatives have been used to develop a group of antimicrobials
commonly knowns as nitroimidazoles [27].
Nitroimidazoles have seen a resurgence in interest due to their broad spectrum of
activity against anaerobic Gram-negative and Gram-positive bacteria. They are particularly
being seen as important in the battle against antibiotic resistance. Resistance to antibiotics
is a major challenge facing modern medicine, and its importance was highlighted in 2016
when it was a topic for discussion at the United Nations General Assembly [28]. It is
estimated that 700,000 people die each year because of infections that are resistant to
current antibiotics and that this figure is predicted to rise to 10 million annually by 2050,
with the global cost forecast to exceed $100 trillion over the next few decades [29]. The
overuse of antibiotics in both clinical and agricultural settings has accelerated the process
of resistance [29,30]. Perhaps the most widely known antibiotic is penicillin, which was
discovered by Fleming in 1928, although it was not produced on any great scale until
1940 [30]. Most current antimicrobials were discovered between the 1940s and 1970s,
including nitroimidazoles in the early 1950s, when azomycin was isolated from a crude
extract of Streptomyces bacteria [31]. This review will look at the role played by NTRs in the
resistance mechanisms of nitroimidazoles.
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2. Nitroimidazoles
Nitroimidazoles are a class of antimicrobial drugs that have a broad spectrum of
activity against anaerobic Gram-positive and Gram-negative bacteria, as well as parasites
and mycobacteria, since their discovery drugs such as metronidazole, pretomanid and
delamanid have gone on to form a large part of the treatment for Helicobacter pylori and
Mycobacterium tuberculosis, respectively. The mode of action of nitroimidazoles can help to
explain why they have such a broad spectrum of activity. They are prodrugs that require the
reduction of the nitro group before they display any antimicrobial effects. This is normally
achieved by NTRs using flavin mononucleotide (FMN) or flavin adenine dinucleotide
(FAD) as prosthetic groups and either NADH or NADPH as reducing agents [27]. The
mechanism is understood to have the following steps: (i) molecules enter the cells through
passive diffusion, (ii) the nitro group is reduced to reactive radical species and (iii) the
radicals react with the DNA or protein within the cell [27]. The reduction of products
within a cell depends on the redox potential of the compound and the number of electrons
being transferred [32]. The system operates more efficiently under anaerobic conditions,
meaning the bactericidal effects are increased compared to when oxygen is present [33].
The complete pathway can be seen in Figure 2. The diverse mode of action, which is often
inadequately defined, can lead to problems when trying to maximise their bactericidal
potential. It is also a factor that must be taken into consideration when looking at the
important issue of resistance.
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Figure 2. Mutagenic pathway of nitroarenes [33].
Resistance to nitroimidazoles usually occurs because there is a decrease in the activity
of the enzymes responsible for the reduction of the nitro group [34]. These resistance
mechanisms differ depending on the target organism and will be described in more depth
in the sections below. To develop new drugs that will aid the management of infectious
diseases, these resistance mechanisms must be better understood.
3. Metronidazole
Metronidazole (MTZ) is a nitroimidazole prodrug derived from azomycin, which
has been used as an antimicrobial since the early 1960s [35]. The drug enters the cells via
passive diffusion but is inactive until the nitro group is reduced. This can occur via two
routes (Figure 3): reductive activation, which results in toxicity, or reductive inactivation,
where the nitro group is reduced to a nontoxic amino derivative [19,36]. MTZ is one of
the main drugs used to treat Helicobacter pylori, which is a Gram-negative microaerophile
bacterium that can be found in the stomach of almost 50% of the world’s population.
The symptoms include chronic gastritis and peptic ulcers. It is also classed as a type I
Biology 2021, 10, 388 4 of 16
carcinogen by WHO, as it is a risk factor in gastric adenocarcinoma and mucosa-associated
lymphoid tissue lymphoma (MALT) [37–39].
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Resistance to MTZ in cases of H. pylori is more common than with other antimicrobials
and can be as high as 80%, depending on the patient group and geographic region [40].
As the mechanism of action requires enzymatic reduction, anything which affects this can
cause resistance. Mutations in the genes that encode certain electron transport proteins
are one such example; inactivation of the rdxA (encodes oxygen-insensitive NADPH
nitroreductase) and frxA (encodes NADPH flavin oxidoreductase) genes is linked to MTZ
resistance in H. pylori [41,42]. Chua et al. [43] demonstrated a strong correlation between
mutations that inactivate RdxA and its resistance. They also reported that a significant
number of MTZ-resistant strains of H. pylori had a mutation of the Arg-16 residue of RdxA.
This amino acid residue is responsible for binding between RdxA and the FMN phosphoryl
group, and therefore, any mutation may adversely affect the reduction of MTZ to its
cytotoxic form [43]. Howev r, this c not be responsible on its own for conferring MTZ
resistance, as it has als been found in H. pylori strains that were susceptible to MTZ [43].
Chua et al. [43] proposed that high lev ls of frxA would c unteract t e effect of Arg-16 and
make H. pylori susceptible to MTZ, espite any mutation of rdxA. If frxA is inactivated, it
does not appear to play a major role n MTZ-resistance but may work together with other
muta ons to ncrea e the resistance [43].
As resistance to MTZ can ccu without either rdxA or frxA inactivation, other mech-
anisms mu t be onsidered [44,45]. One such mechanism suggested by Lee et al. [46] is
a gene, hefA, associated with the efflux p mp HefABC. The expression of this gene is
increased when exposed to MTZ. In MTZ-resistant strains of H. pylori wit intact frxA
and rdxA, t levels of hefA were higher than in su ceptible strains. If hefA w s knocked
out, the strains became sensitive to MTZ, a d this was reversed by the addition of hefA,
showing that hefA was directly involved in MTZ-resistance [46]. While this could help to
explain cases of MTZ resistance in the presence of functioning frxA and rdxA genes, the
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overexpression of hefA alone does not result in resistance [46]. Clearly, the resistance of
H. pylori to MTZ is a complex mechanism that requires further study to fully understand.
Nitroimidazole resistance at low levels is often associated with the nim genes [47]. The
Nim genes were first described in 1994 [48], and their nitroreductase activity was observed
two years later when a nimA-positive strain of Bacteroides fragilis reduced a nitroimidazole
drug to its noncytotoxic amine derivative [49]. Currently, eleven nim genes have been
identified: nimA–nimK [50].
The exact mechanism of nim resistance is not fully understood, and there is conflicting
evidence for the role of nim genes in metronidazole (MTZ) resistance [50,51]. Figure 4 below
shows the involvement of nim genes in the mechanism and resistance of metronidazole.
The overexpression of nimA, nimE and nimJ induces an increase in MTZ resistance in E. coli
and B. fragilis, respectively [52,53].
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However, several Bacteroides spp. and genera within the Clostridia class are resis-
tant to MTZ without containing the nim gene, while other nim-positive species are MTZ-
susceptible [54–58]. Thus, the p esence of a nim gene does not automatically equal re-
sistance. Gal et al. [54] found that only about half of the 50 Bacteroides strains positive
for the nim gene presented minimum inhibitory concentrations (MICs) ranging from 16
to >32 µg/mL—therefore, above the resistance breakpoint. Sethi et al. [59] looked at the
MTZ resistance rates in India and the relationship of isolates positive for a nim gene with
resistance. They found a relatively high rate of resistance (31% compared to <1% in Europe),
with a 53% rate of positivity for the im g ne. Out of 20 samples, 12 that w re positive for
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the nim gene also showed resistance to MTZ, a significant correlation [59]. Leitsch et al. [60]
ascertained the levels of expression of the nim genes using 2D gel electrophoresis (2DE). The
study looked at whether adaptation to an increased concentration of MTZ led to increased
levels of the nim protein. As nim proteins are thought to act as nitroreductases that reduce
MTZ to its noncytotoxic form, their profusion should correlate with high levels of MTZ
resistance. To test this theory, a high-level MTZ resistance was induced in three strains of B.
fragilis, but when the nim levels were measured, there was found to be no upregulation [60].
Such studies reinforce the complexity of MTZ resistance mechanisms and emphasise that
nim genes alone are not sufficient to give high-level MTZ resistance [53,54,56]. Nim genes
have been found in multidrug resistant strains of B. fragilis, together with other resistance
genes [61]. A cluster of multidrug-resistant (MDR) B. fragilis isolates containing nimB, cfiA,
ermF and tetQ genes was detected using whole-genome sequencing (WGS) [61]. Nim genes
have also been found in an MDR strain of B. thetaiotaomicron together with two β-lactamase
genes, two tetX genes—tetQ and ermF—two cat genes and several genes encoding efflux
pumps [62]. Despite this current inability to definitively demonstrate the cause and effect
of nim genes and MTZ resistance, it is still worthy of further investigation as important
risk factors, such as the location of the nim genes on mobile genetic materials plus the
high usage of MTZ as a frontline drug in multiple infectious diseases could lead to an
increase in resistance [50]. This is underlined by the presence of nim genes in several MDR
anaerobes [63].
4. Delamanid and Pretomanid
Delamanid and pretomanid are both bicyclic 4-nitroimidazoles, and phase II clinical
trials have shown them to be effective against both replicating and hypoxic nonreplicating
mycobacteria [64]. Tuberculosis (TB) is the leading cause of death from infectious disease.
In 2018, 10 million people became ill with TB, with 1.2 million deaths [65]. Under aerobic
conditions, the mechanism of action is to inhibit the formation of mycolic acids [66],
while under anaerobic conditions, the mechanism induces respiratory poisoning [67].
Pretomanid, in particular, donates nitric oxide (NO), which can create toxic conditions
within the bacilli in nonreplicating MTB [67]. Both delamanid and pretomanid are prodrugs
that require bioactivation of the nitro group to become effective. They are activated in an
F420H2-dependant reaction in MTB by deazaflavin-dependant nitroreductase (Ddn) [67,68].
Therefore, mutations that affect the activity of Ddn or the biosynthesis or reduction of F420
may result in resistance [64].
Delamanid (Figure 5) was discovered by Otsuka Pharmaceuticals [69] and was granted
conditional approval in 2014 by the European Medicines Agency (EMA) for the treatment
of pulmonary MDR-TB in adults in combination with other frontline drugs [70].
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The World Health Organisation (WHO) issued a policy guidance, which stated that
delamanid could be added to the WHO-recommended regimen [71]. It has a potent
minimum inhibitory concentration (MIC) range of 6–240 ng/mL, which is the lowest among
the current TB drugs [69,72]; plus, it showed no signs of toxicity in the Ames test [73].
In a phase IIa trial, delamanid showed good activity in drug-susceptible TB patients,
but due to poor adsorption at high doses, twice-daily dosing was required (2 × 50-mg
tablets per dose) [74,75]. The compound works by inhibiting the synthesis of cell wall
com onents and is active ag inst replicating and nonreplic ting persister bacteria, both
extra and intracellular bacilli [69]. It does not show a cross-resistance with other TB drugs
and can therefore be used in combinations [76]. A phase II trial was completed in 2012
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in combination with an optimised background regime (OBR) in 17 centres across nine
countries [77]. Phase III trials have since been completed, and further investigations into
its use in children are underway [77].
Dormant bacteria are often resistant to treatment, and therefore, new drugs with the
ability to kill dormant bacilli are more likely to be effective against MDR-TB. The Wayne
model is being used to test the efficacy of TB drugs under low oxygen concentrations [78,79].
Various studies have used a modified version of this model to investigate the bactericidal
effects of delamanid in aerobic versus anaerobic settings, with Upton et al. [80,81] showing
that it killed 99% of MTB bacilli at 4.4 µg/mL. Delamanid was also as effective as the
frontline drug rifampicin against intracellular mycobacteria [82].
A resistance to delamanid has been reported in clinical isolates of TB. Bacilli resistant
to delamanid have mutations in one of the five genes (Figure 6) associated with the F420-
dependant nitroreduction pathway: fgd1, ddn, fbiA, fbiB and fbiC [83]. FbiA, fbiB and
fbiC are coded for proteins FbiA, FbiB and FbiC, which are essential for the biosynthesis
of F420, with each gene affecting a different stage [84,85]; fgd1 (gloucose-6-phospahte
dehydrogenase) play a role in the F420 redox recycling mechanism and ddn is the reductase
required for activation [86].
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Fujiwara et al. [86] showed that, from 30 randomly selected resistant colonies, the
frequency of mutations across the five genes varied considerably: ddn (20%), fgd1 (30%), fbiA
(16.7%), fbiB (6.7%) and fbiC (26.7%). The fact that resistant bacilli lack the ability to activate
delamanid is shown by the following; when drug-susceptible MTB bacilli were incubated
with delamanid, the concentration decreased as it was converted to the des-nitroimidazole
form, but when resistant bacilli were used, no change was seen [82,86].
Pretomanid (Figure 7) was identified by PathoGenesis and was approved by the FDA
in 2019 for the treatment of multidrug-resistant TB in combination with bedaquilne and
linezolid [87]. The MIC values range from 150 to 250 ng/mL, and no cross-resistance with
other TB drugs has yet been seen, making it a good candidate for treating MDR-TB [88].
Studies have shown that pretomanid, in combination with moxifloxacin and pyrazinamide,
had better bactericidal activity than the current standard regimen [89,90]. The primary
mechanism of action is the inhibition of synthesis of cell wall lipids and proteins [91].
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Resistant mutants have shown that both Ddn and FGD1 are essential for the drug to
become activated; however, only Ddn is involved in reducing the nitro group, producing
three primary metabolites and reactive nitrogen species [67]. A study by Haver et al. [88]
looked at 183 spontaneous pretomanid-resistant mutations of which 29% of the lesions
were seen in ddn, 26% in fbiC, 19% in fbiA, 7% in fgd1 and 2% in fbiB; the remaining 17% did
not show mutations in any of the five genes. Eighty-three percent had single mutations in
one of the genes. As 17% had no mutations within the five genes, it can be hypothesised
that other targets are involved in either the mechanism of action or activation pathway of
pretomanid [88].
As stated previously, mutations that knock out the activity of Ddn completely may
result in resistance in both delamanid and pretomanid. However, this could affect the fitness
of MTB, as the cofactor F420 has been shown to be essential for the survival of MTB, used by
at least 28 enzymes [92] that play important roles in the hypoxic recovery and evasion of the
hosts immune system [93,94]. Therefore, in order for nitroimidazole resistance to spread,
the native activity of Ddn must either be retained or compensated for. The activation of
delamanid and pretomanid by Ddn is a promiscuous activity that is more prone to mutation
than native functions [95], meaning that the prodrug activation could be lost without loss of
the native function. Lee et al. [96] conducted studies to better understand the fitness costs of
the loss of Ddn activity. They were able to demonstrate, through studying 75 mutants, that
a number were able to prevent the activation of pretomanid without the loss of all native
functions. Therefore, these mutants would be fit enough to spread to new patients [96].
These mutations are likely to be one of the main routes through which resistance to these
two new TB drugs will spread. Of the 75 mutants studied, 25 did not reduce pretomanid,
but only 10 lost the ability to reduce delamanid, despite their similarities, suggesting
that they interact with Ddn in different ways [96]. Clearly, the results from this study
should be considered when looking at the continued development and clinical use of
nitroimidazoles. Both delamanid and pretomanid are undergoing phase II/III trials, in
combination with other drugs, against drug-susceptible TB and MDR-TB. Mutations of
Ddn should be closely monitored to ensure that the best drug combination is used, and
that will ultimately reduce the spread of resistance. The indication that delamanid binds to
Ddn differently than pretomanid means that it could be used to treat some TB strains that
are resistant to pretomanid [96]. A combination of the two could also be used to reduce the
spread of resistance. Further testing of a range of nitroimidazoles against a variety of Ddn
variants could help to identify drugs which are less likely to develop resistance.
To fully understand the resistance mechanism, Fujiwara et al. [86] suggested that a
rapid drug susceptibility test should be developed. Presently, only phenotypic tests are
available for delamanid based on cultures, with results taking several weeks [97]. However,
the development of a molecular based test has been problematic due to the distribution of
mutations across five genes [86].
One reason why drugs containing a nitro group have not been more widely used
is because of the associations with toxicity, including bone marrow suppression, hepato-
toxicity and carcinogenicity [16]. Both types of nitroreduction (I and II) produce toxicity;
in type I, this is as a result of the generation of hydroxylamine, and during type II, the
generation of reactive oxygen species (ROS) via redox cycling causes pharmacological
activity [98]. Therefore, if they are going to play any part in the fight against drug resistance,
any new developments must aim to reduce these issues. Drugs such as delamanid and
pretomanid have been shown to not be mutagenic or genotoxic, but their use is hampered
by issues with solubility. This is an area that could be further investigated by formulation
chemists [16].
5. Chloramphenicol
The ever-increasing resistance to modern antibiotics has led to the re-evaluation of
drugs that had either limited use or were discarded due to toxicity or efficacy issues. One
such antimicrobial that is now being reassessed is chloramphenicol [99,100]. Chlorampheni-
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col can cross the blood–brain barrier and other sites that can be hard to target, which makes
it a powerful drug in the treatment of bacterial meningitis [99]. However, chloramphenicol
has also been linked with haematological toxicity [101], and its use is carefully controlled in
developed countries [101]. As a possible consequence of this, it can still be effective against
multidrug-resistant organisms, including MRSA [102,103].
The main mechanisms of chloramphenicol resistance occur through functions such
as enzymatic inactivation via chloramphenicol acetyltransferance, efflux pump removal
and ribosome protection [104]. The bacterial modification of chloramphenicol was first
reported only two years after it was discovered. Several species of bacteria were reported
as being able to reduce the nitro group, with the resulting compound having no antimi-
crobial effect [104]. Crofts et al. [104] set out to identify the bacterial genes that could be
involved in this reduction mechanism. They chose to focus on type I oxygen-insensitive
nitroreductases—in particular, NfsB from Haemophilus influenzae. They determined the
ability of H. influenzae NfsB to reduce the nitro group of chloramphenicol completely to an
amine. The reduction is enough to confer resistance to chloramphenicol, but Crofts et al.
observed that the H. influenzae NfsB enzyme also uses metronidazole (MTZ) as a substrate
but does not completely reduce the nitro group. They hypothesised that, while NfsB
protects the cell against chloramphenicol, it activates MTZ to its cytotoxic state, therefore
offsetting any survival benefits. They concluded that the two drugs could be used together
to combat bacteria resistant to chloramphenicol on its own [104].
One of the reasons that chloramphenicol has not been more widely used is the concern
that its use could result in the development of aplastic anaemia [105]. The mechanism
through which this happens is not fully understood, although it is thought that nitro
reduction is involved. The identification of a bacterial enzyme that has been shown to
reduce chloramphenicol means that this theory can now be tested and hopefully identify
analogues of chloramphenicol that can be used in the clinic [104].
6. MT02
The antimicrobial drug MT02 has been identified as a new candidate that is active
against Gram-positive bacteria such as Staphylococcus aureus [106]. S. aureus is a common
pathogen associated with a wide range of infections, both superficial and invasive [107].
Together with S. epidermidis, it accounts for more than 20% of all infections associated
with hospitalisation, affecting over 250,000 patients in the USA and Europe annually [107].
The first antibiotic used to treat S. aureus was penicillin; prior to this, the infection was
normally fatal [108]. Resistant strains soon appeared, which, in turn, stimulated the search
for new antibiotics in the 1950s, such as streptomycin and tetracycline, but resistance soon
developed once they were being routinely used in the clinic [109,110]. The development of
methicillin was a result of the search for an antibiotic that would be active against penicillin-
resistant S. aureus. Methicillin-resistant S. aureus strains (MRSA) emerged in the 1960s,
rendering the drug ineffective [111]. MT02 is a nitro-active compound, and the work carried
out by Menzel et al. [106] in 2011 showed that it is a DNA-binding compound leading to the
inhibition of DNA replication. It shows high levels of antimicrobial activity against S. aureus
and other Gram-positive bacteria [106]. El-Hossary et al. [112] carried out further work to
identify the potential of S. aureus to develop resistance to MT02 [112]. In order to select
MT02-resistant clones, S. aureus strain MA12 was cultivated with increasing concentrations
of MT02. Once the concentration reached 10 µM, a red colour began to appear, which
then intensified with increasing concentrations. Work to identify the structure of this red
compound showed the stepwise reduction of the aromatic nitro groups of MT02 to amino
groups. The conclusion was that this reduction was induced by an enzyme found in the
resistant S. aureus strain [112]. Four previously identified enzymes with nitroreductase
activity (SAUSA300_0788, SAUSA300_0381, SAUSA300_1986 and SAUSA300_2462) were
found not to be responsible for this reduction of MT02 [112]. The group carried out
total RNA sequencing (RNA-seq), which identified the overexpression of an assumed
nitroreductase SAUSA300_0859. This was confirmed by RT-PCR, which showed a 160-
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fold overexpression of SAUSA300_0859 in the MT02-resistant strain. The importance of
SAUSA300_0859 in the development of resistance to MT02 was confirmed when sensitivity
was restored by a transposon insertion mutant. A biochemical analysis showed that the
SAUSA300_0859-encoded protein produced an intense red colour when incubated with
MT02, demonstrating that it is the functional enzyme giving resistance in S. aureus [112].
While the molecular mechanism that leads to the overexpression of SAUSA300_0859 is not
known, this is thought to be the first example of a nitroreductase-based antibiotic resistance
mechanism in S. aureus.
7. Future Perspectives
As resistances to antimicrobials continue to grow, finding alternatives is crucial. As
this review demonstrated, nitroimidazoles have a broad range of activity against many
different organisms, and it would therefore be prudent to re-examine their potential.
Several strategies that merit further investigation are briefly discussed below.
As well as looking for ways to combat the issue of toxicity, the mechanism of nitroimi-
dazole resistance must be fully understood if effective drugs are to be developed. What is
clear from the discussions above is that the role played by nitroreductases needs further
investigation. This is of particular importance, as many bacteria have developed resistance
to multiple drugs [113]. Strategies that aim to directly combat different resistance mech-
anisms are more likely to be effective in finding ways to treat drug-resistant organisms.
The repurposing of existing antimicrobials and their use in novel combinations is one such
strategy. Drug repurposing is defined as “an approved drug in one disease area is found
to be active in another disease whereas drug repositioning is the uses of a drug active in
one disease as a template for the synthesis of derivatives active in another disease” [114].
Drug rescue is defined as “developing new uses of a drug that failed to progress through
clinical studies or which was removed from the market” [114]. All these strategies have
been applied to nitroimidazoles.
Collaboration is important in drug development and repurposing. Open databases
provide cost-effective access to the sharing of resources and data. Examples include Pub-
Chem and Chemspider, which contain chemical structural information, while DrugBank
and SuperTarget provide profiles of drugs and target diseases [115]. As NTRs have such
a broad spectrum of activity, the use of these databases presents a useful tool. For exam-
ple, entering “nitroimidazole” as a search in PubChem (December 8th, 2020) identified
3479 molecules in the compound database and 1754 records in the Bioassay database.
Research groups can use these databases to profile nitroimidazoles against a much greater
number of microorganisms than would have previously been possible. This could poten-
tially identify those with untapped potential. Along similar lines, the open innovation
concepts, such as the Community for Open Antimicrobial Drug Discovery (CO-ADD)
funded by the Wellcome Trust and The University of Queensland, encourage the open
sharing of data and ideas. These initiatives aim to remove any barriers that could limit
an individual group’s ability to develop suitable compounds by making resources widely
available. This is particularly relevant to NTRs, as their complex modes of action require
extensive investigation to fully understand [27].
As previously discussed, NTRs can be used as prodrug activators. Celik et al., [116]
investigated the potential for NTRs to be used in antibiotic activation. They aimed to
identify possibilities for redesigning existing drugs as precursor prodrugs that could then
be activated by bacterial NTRs. They redesigned sulfamethoxazole as a prodrug, and
when this was activated by a type I NTR, the results showed an improved antimicrobial
action, thus demonstrating that the use of existing approved antibiotics in the form of
pre-antibiotics could be used against disease-causing bacteria [116]. The use of antibi-
otic adjuvants is another strategy that has been shown to work [117]. These are small
molecules that, although they have no antimicrobial actions, can increase the efficiency of
antibiotics [114].
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The development of more robust vaccines for TB would see the need for aggressive
treatments with antibiotics reduced. One such area of research is the use of latency-
associated antigens, particularly those encoded by the dormancy survival regulator (DosR)
regulon [118]. The current BCG vaccine offers poor protection against adult TB [119], as
it does not protect against the bacteria when they are in the dormant phase. As most TB
patients have a latent infection before any clinical signs are present, latency-associated
antigens that are expressed during the dormant phase are of interest as potential vaccine
candidates. Kwon et al. [120] selected Rv3131, which is a hypothetical NTR with two
DosR-binding sites, as a vaccine candidate. They aimed to investigate whether Rv3131 had
any potential as a vaccine against TB. They concluded that it showed promise, as it met the
following criteria: it was recognised by the immune system in in vivo experiments, could
induce Ag-specific Th-1 T cells and showed activity against highly virulent TB strains [120].
8. Conclusions
This review has shown that nitroreductases play an important role in drug activation
but are also associated with resistance mechanisms. This review highlighted the urgent
need for further investigations to fully understand these mechanisms before they can be
utilised against multidrug-resistant organisms for the development of new drugs. This
will depend on the committed collaborations between the private and public sectors to
translate academic research into the clinic.
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